Phase I study of zactima (ZD6474) [vandetanib] plus imatinib mesylate and hydroxyurea [hydroxycarbamide] for patients with recurrent malignant glioma.

Trial Profile

Phase I study of zactima (ZD6474) [vandetanib] plus imatinib mesylate and hydroxyurea [hydroxycarbamide] for patients with recurrent malignant glioma.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2012

At a glance

  • Drugs Vandetanib (Primary) ; Hydroxycarbamide; Imatinib
  • Indications Glioma
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Aug 2012 Trial phase changed from II to I as reported by ClinicalTrials.gov.
    • 11 Oct 2011 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
    • 11 Oct 2011 Status changed from active, no longer recruiting to completed as reported by the ClinicalTrials.gov record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top